Biocytogen and Neurocrine Biosciences Sign an Antibody Evaluation and Option Agreement
Shots:
- Under the agreement, Neurocrine gains access to Biocytogen's fully human antibodies against designated targets, and it has the option to license specific antibodies for use in the development, production, and global marketing of therapeutic products. Targets may be added if both parties agree
- Biocytogen will receive option-exercise fees, development and commercialization milestone payments along with single-digit royalties on net sales for each selected target if it exercises the options mentioned in the agreement
- Additionally, Biocytogen’s proprietary RenMice platforms has been utilized to produce the antibodies
Ref: Biocytogen| Image: Biocytogen
Related News:- Biocytogen Entered into a License Agreement with Pheon Therapeutics to Develop Antibody-Drug Conjugate for Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
